During the recent session, Novabay Pharmaceuticals Inc (AMEX:NBY)’s traded shares were 0.47 million, with the beta value of the company hitting 0.71. At the last check today, the stock’s price was $0.76, reflecting an intraday loss of -6.16% or -$0.05. The 52-week high for the NBY share is $9.08, that puts it down -1094.74 from that peak though still a striking 52.63% gain since the share price plummeted to a 52-week low of $0.36. The company’s market capitalization is $3.72M, and the average intraday trading volume over the past 10 days was 0.78 million shares, and the average trade volume was 573.79K shares over the past three months.
Novabay Pharmaceuticals Inc (NBY) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. NBY has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
Novabay Pharmaceuticals Inc (AMEX:NBY) trade information
Novabay Pharmaceuticals Inc (NBY) registered a -6.16% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -6.16% in intraday trading to $0.76, hitting a weekly high. The stock’s 5-day price performance is 11.78%, and it has moved by 50.78% in 30 days. Based on these gigs, the overall price performance for the year is -86.08%. The short interest in Novabay Pharmaceuticals Inc (AMEX:NBY) is 62921.0 shares and it means that shorts have 0.38 day(s) to cover.
Novabay Pharmaceuticals Inc (NBY) estimates and forecasts
Statistics show that Novabay Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Novabay Pharmaceuticals Inc (NBY) shares have gone down -64.31% during the last six months, with a year-to-date growth rate more than the industry average at 97.22% against 16.90.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 24.47%. While earnings are projected to return 97.65% in 2025.
NBY Dividends
Novabay Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Novabay Pharmaceuticals Inc (AMEX:NBY)’s Major holders
Novabay Pharmaceuticals Inc insiders own 0.02% of total outstanding shares while institutional holders control 10.32%, with the float percentage being 10.32%.
Also, the Mutual Funds coming in first place with the largest holdings of Novabay Pharmaceuticals Inc (NBY) shares are Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund. Data provided on Nov 30, 2024 indicates that Fidelity Extended Market Index Fund owns about 25.68 shares. This amounts to just over 0.52 percent of the company’s overall shares, with a $19517.0 market value. The same data shows that the other fund manager holds slightly less at 7.35, or about 0.15% of the stock, which is worth about $5585.0.
